124 related articles for article (PubMed ID: 33270252)
1. Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875).
Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Safrygin A; Krasavin M
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000275. PubMed ID: 33270252
[TBL] [Abstract][Full Text] [Related]
2. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
[TBL] [Abstract][Full Text] [Related]
3. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
4. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel potent GPR40 full agonist.
Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
[TBL] [Abstract][Full Text] [Related]
6. Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S; Ihalainen J; Forsberg MM; Lehtonen M; Rautio J; Moore D; Tikhonova IG
Bioorg Med Chem; 2016 Nov; 24(21):5481-5494. PubMed ID: 27647366
[TBL] [Abstract][Full Text] [Related]
7. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K
Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059
[TBL] [Abstract][Full Text] [Related]
8. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
Negoro N; Sasaki S; Mikami S; Ito M; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Morohashi A; Nonaka M; Matsunaga S; Yasuma T; Momose Y
J Med Chem; 2012 Apr; 55(8):3960-74. PubMed ID: 22490067
[TBL] [Abstract][Full Text] [Related]
9. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel orally bioavailable GPR40 agonists.
Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
[TBL] [Abstract][Full Text] [Related]
11. Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):29-36. PubMed ID: 27781494
[TBL] [Abstract][Full Text] [Related]
12. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
13. Ligands at Free Fatty Acid Receptor 1 (GPR40).
Hara T
Handb Exp Pharmacol; 2017; 236():1-16. PubMed ID: 27757762
[TBL] [Abstract][Full Text] [Related]
14. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.
Negoro N; Sasaki S; Ito M; Kitamura S; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
J Med Chem; 2012 Feb; 55(4):1538-52. PubMed ID: 22242551
[TBL] [Abstract][Full Text] [Related]
15. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG
Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825
[TBL] [Abstract][Full Text] [Related]
16. The Role and Future of FFA1 as a Therapeutic Target.
Ghislain J; Poitout V
Handb Exp Pharmacol; 2017; 236():159-180. PubMed ID: 27807697
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARĪ“ agonists possessing phenoxyacetic acid scaffold.
Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
19. GPR40-Mediated G
Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
[TBL] [Abstract][Full Text] [Related]
20. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
Kaku K
Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
